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Summary objective To evaluate a pilot intervention to engage a patient tracer to follow up lost patients at a
large public clinic in South Africa.
methods A social worker spent 4 months contacting by telephone a random sample of patients who
had initiated antiretroviral therapy (ART) at least 6 months earlier and were ‡1 month late for a
scheduled visit. The tracer was authorized to assist patients to return to care if needed. Cost was
calculated from the perspective of the clinic.
results The tracer was able to determine the ﬁnal status of 260 of a sample of 493 lost patients. Of the
260, 55 (21%) had died, 56 (21%) were still on ART at the same site, 79 (30%) reported transferring to
another site and 70 (27%) had discontinued treatment. Among those discontinuing, commonly cited
reasons were relocation (n = 18, 26%), traditional medicine or religious beliefs (n = 11, 16%), fear of
disclosure or other family barriers (n = 9, 13%), and employment obstacles (n = 7, 10%). Twenty
patients returned to care at the original site as a result of the intervention, at an average cost of $432 per
patient returned.
conclusions A patient tracer was an effective way to determine the ﬁnal status of lost patients and
succeeded in returning some to care, but the cost per patient returned was high. Better information
systems allowing sites to track deaths and transfers would greatly improve the efﬁciency of loss to
follow-up interventions.
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Introduction
As large, public sector programs for providing antiretro-
viral therapy (ART) for HIV⁄AIDS have expanded and
matured in sub-Saharan Africa, high rates of patient
attrition from the programs have become apparent.
While much attrition is due to mortality, loss to follow-
up – the disappearance of the patient from the program,
for no reported reason – is even more common. A
systematic review of cohort studies from the region
published between 2007 and 2009 found that loss to
follow-up comprised an average of 59% of all reported
attrition in the ﬁrst year of treatment (Fox & Rosen
2010). Roughly 25% of all patients who initiated ART
had been lost to follow-up or had died 2 years after
starting treatment.
Loss to follow-up is a difﬁcult issue to study and to
address, because the patients involved have opted out of
care, either voluntarily or involuntarily, and thus cannot
readily be reached. Providers typically do not know
whether a lost patient has died; transferred to a new
treatment site; been unable to remain in care due to
economic, social or psychological barriers; or simply
chosen to discontinue treatment. In a study of reasons for
loss to follow-up among patients on ART for 18–
48 months at a public hospital in Johannesburg, we found
that some patients who had dropped out of the treatment
program were willing to return to care but needed help in
overcoming a relatively minor obstacle, such as the
inability to provide the documentation that they believed
would be required by the clinic or a fear of being chastised
by the clinic staff. Others faced more structural but also
solvable problems, such as lack of a small amount of
money for transport to the clinic (Miller et al. 2010).
One intervention that has been tried by a number of
treatment sites is to try to contact lost patients by cell
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determining their status or, more ambitiously, of helping
them to return to care. These experiments with ‘patient
tracers’ have often proven effective in determining the
status of lost patients (Geng et al. 2008). Success in
returning patients to care has been more mixed (Billy et al.
2007; Ochieng et al. 2007; Krebs et al. 2008; Tweya et al.
2009). In Kenya, for example, phone calls and home visits
resulted in 65% and 49% of traced patients returning to
care in an urban and rural area, respectively (Ochieng et al.
2007). A follow-up intervention in Malawi, however,
resulted in only 19% of all lost patients returning to care
(Tweya et al. 2009). In Zambia, an average of 18 home
visits to lost patients in an urban setting was required per
patient who ultimately returned to care (Krebs et al. 2008).
As the study of home visits in Zambia suggests, many
contacts with patients who cannot be returned to care may
be required for each one who does return. For large,
public-sector treatment facilities in resource-constrained
settings, this raises the issues of feasibility and affordabil-
ity, both in an absolute sense and relative to other potential
interventions for reducing loss to follow-up (Losina et al.
2009). To help one treatment program in South Africa
address this issue, we conducted a cost-effectiveness
analysis of a pilot ‘patient tracer’ intervention that the site
implemented over a 4-month period in 2009.
Methods
Study site
The intervention was implemented at Themba Lethu
Clinic, the HIV⁄AIDS clinic of Helen Joseph Hospital in
Johannesburg, South Africa. Themba Lethu, one of the
oldest and largest providers of antiretroviral treatment in
South Africa, provides some 12 000 adult patients with
ART. It is funded primarily by the Gauteng Province
Department of Health, with technical and ﬁnancial support
from Right to Care, a non-governmental partner of the
U.S. President’s Emergency Plan for AIDS Relief (PEP-
FAR). The site has been described in numerous publica-
tions (Sanne et al. 2005; Maskew et al. 2007; Rosen et al.
2007, 2008a,b,c; Dalal et al. 2008).
Antiretroviral therapy patient loss to follow-up at
Themba Lethu Clinic is in line with other estimates from the
region. Of roughly 7500 patients initiated on ART in the
ﬁrst 3 years of the program (April 1, 2004–March 31,
2007), 16.4% had been lost to follow-up by March 31,
2008. Nearly 40% of these were lost in their ﬁrst 3 months
on ART, and the rest over the following 4 months to
4 years (Majuba et al. 2009). An analysis of a smaller
cohort of 200 patients initiated on ART at Themba Lethu in
2005 estimated a 24-month loss to follow-up rate of 29%
(Long et al. 2008). Clinic staff believes that patient reten-
tion has improved since then, as has the tracking of patient
mortality, but loss to follow-up almost certainly remains in
double digits even for the most recent patient cohorts.
Description of intervention
The intervention was limited to adult patients who had
initiated ART at Themba Lethu Clinic in or after April
2004, had been on ART for at least 3 months at their last
clinic visit, were between 1 and 12 months late for their
next scheduled visit or medication pickup, and were not
known to have died or transferred to another treatment
site. All patients meeting these criteria were identiﬁed
through the clinic’s electronic information system and then
stratiﬁed into four groups on the basis of duration on ART
(less than or more than 1 year as of last clinic visit) and
CD4 count at most recent test (less than or more than
350 cells⁄mm
3). Finally, patients in each group were
selected at random for inclusion in the intervention.
Although Themba Lethu Clinic has for several years
employed a counsellor to track patients lost to follow-up,
this counsellor is generally limited to making one or two
phone calls to the contact numbers provided by patients to
determine their status and is not authorized to provide any
speciﬁc assistance to help patients return to care. The
intervention evaluated by this study engaged a researcher
with training in social work to serve as an enhanced patient
tracer on an 80% time basis (4 days⁄week) for 4 months.
The researcher engaged for this purpose was a university
graduate who was employed by a research unit attached to
the study clinic. She was very familiar with the clinic and
had implemented other studies at the site, including
conducting qualitative interviews with patients who had
been lost to follow-up. During the implementation of the
intervention, the researcher was seconded to the study
clinic and operated as a member of the clinic staff.
In the role of patient tracer, the researcher was instructed
to use all available contact information to locate patients;
discuss the patient’s situation by phone or in person; and,
following pre-established guidelines, assist the patient to
return to care. Assistance allowed by the intervention’s
guidelines included making an appointment at the clinic on
the patient’s behalf; meeting the patient for the appoint-
ment and assisting in the consultation if requested; helping
to obtain documentation required to continue treatment;
ﬁnding and referring the patient to another treatment
facility closer to the patient’s home or open at different
times; helping the patient to disclose his⁄her HIV or
treatment status to family members; providing other
information or referrals as requested; and⁄or providing up
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fares to and from the clinic. The intention of providing
transport funds was to allow the patient to make one
additional roundtrip visit to the clinic, in the hope that the
clinic staff could assist the patient in devising a longer-term
solution to the lack of transport funds, such as transferring
to a closer facility or applying for a social support grant.
The intervention was implemented between February 10
and June 10, 2009. Both initial and follow-up contacts
were made in the ﬁrst 3 months of the intervention. The
fourth month was limited to follow-up contacts only,
ensuring that all patients who were contacted had at least
1 month to return to care before the intervention was
completed and evaluated.
Data analysis
The patient tracer maintained detailed records of all
attempts to contact patients, successful contacts, patient
status, recommendations or assistance given, and costs
incurred. Aggregate outcomes for evaluation included
number of previously lost-to-follow-up patients known to
have returned to care at the study site or another facility as
a result of the intervention and number of previously lost-
to-follow-up patients whose status was newly determined
by the intervention. The average cost to achieve each
outcome was then estimated. Intervention costs included
the tracer’s salary and beneﬁts, the cost of a workstation at
the site, and equipment, phone and transport charges. To
consider the costs if the tracer’s salary had been that of
nurse at the clinic, rather than a researcher employed
externally, a second analysis was run using the current
salary of a government junior enrolled nurse.
Results
Sample
Of approximately 11 700 patients who had started ART at
the study clinic by the end of September 2008 and could
thus have been on treatment for at least 3 months at the
time of sample selection, 869 patients met all the inclusion
criteria for the intervention as of January 8, 2009, as
illustrated in Figure 1. A random sample of 493 (57%) of
these patients was selected for follow-up by the tracer.
Over 4 months, the tracer was able to reach or learn the
status of 260 (53%) patients. The remaining 233 (47%)
could not be located using contact information provided to
the clinic by the patients. As shown in Table 1, patients
whose last reported CD4 count exceeded 350 cells⁄mm
3
Figure 1 Status of patients in intervention.
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lower CD4 counts at their last visit.
Among those reached, all but one patient were contacted
by telephone only; at the patient’s request, one contact was
made in person, at the patient’s home. The tracer made a
total of 883 phone calls in the 4-month period, or an
average of 1.8 calls per patient in the sample. Each patient
was called between 0 and 8 times. One hundred and forty
patients did not provide any contact information and could
not be called at all (0 calls). Among the 353 who were
called at least once, the average number of calls⁄patient
was 2.5. Of these, 93 patients were not found by phone
(calls not answered or answered by someone who did not
know the patient or did not know the patient’s location or
status). The status was determined for the remaining 260.
Tracing results
The status of the 260 patients who could be traced is
shown in Table 2. Approximately one ﬁfth of the sample
was reported by household members to have died. Another
ﬁfth told the tracer that they were still on treatment at the
same facility; of these, roughly half said that they had not
missed any appointments, indicating an error in the site’s
record-keeping. The other half had interrupted their
treatment temporarily, justifying the notation of lost to
follow-up in their records, but returned to the clinic during
the intervention period.
Nearly a third of the sample (30%) reported that they
had transferred to another ART facility, either nearby or in
a different province or country. Those transferring locally
generally cited transport cost as the reason for transferring,
though several said that they were now attending a nearby
clinic that was open on Saturdays to avoid conﬂict with
work schedules. Most of those who transferred to more
distant sites indicated that they had returned to their
original homes after living in Johannesburg temporarily.
Finally, the remaining 27% of patients traced had
discontinued treatment for a variety of reasons, as shown
in Table 3. Approximately a quarter of these patients
reported that they had left Johannesburg and had not re-
started treatment at a new facility, though some indicated
that they still intended to do so. The next largest group –
16% of the total – cited traditional medicine or religious
Table 1 Proportion of sampled patients
located by tracer, by duration on ART and
last CD4 count
Duration on ART
at time of loss
to follow-up Number traced⁄number in sample (%)
Last reported CD4
count (cells⁄mm
3) <350 >350 All
On ART <1 year 59⁄107 (55%) 9⁄10 (90%) 68⁄117 (58%)
On ART >1 year 120⁄260 (46%) 72⁄116 (62%) 192⁄376 (51%)
All 179⁄367 (49%) 79⁄126 (63%) 260⁄493 (53%)
ART, antiretroviral therapy.
Table 2 Status of patients traced during intervention
Status n %
Died (as reported by person answering
contact phone number)
55 21
Still on ART at site 56 21
No interruption (records incorrect) 29 52
With interruption; temporary loss to
follow-up
27 48
Transferred to a different site 79 30
Local treatment site (within Gauteng
Province)
29 37
Distant treatment site (different
province or country)
39 50
Private sector provider 11 13
Discontinued treatment 70 27
Total 260 100
ART, antiretroviral therapy.
Table 3 Patients’ stated reasons for discontinuing treatment
Reason n %
Relocated, did not re-start treatment
in new location
18 26
Traditional medicine, religious beliefs,
religious training
11 16
Fear of disclosure or other family barriers 9 13
Conﬂict with employment obligations 7 10
Undergoing TB treatment 6 9
Cost of transport 6 9
Side effects 3 4
Too ill to visit clinic 1 1
Believed ART would prevent pregnancy 1 1
No reason provided 8 11
ART, antiretroviral therapy.
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these, 4 of the 11 patients said that they believed they had
been cured of HIV and no longer needed treatment. A
number of patients were unwilling to remain in care due to
fear of disclosure of their HIV status to their partners or
families or for other family-related reasons. Several others
expressed fear of losing their jobs if they took time off to
attend the clinic. A variety of other reasons were cited by
smaller numbers of patients, as shown in Table 3.
Over the course of the 4-month intervention, the tracer
was able to persuade 20 of the 97 patients (21%) who had
voluntarily discontinued treatment prior to being contacted
by the tracer to return to the clinic. Each of these 20
patients completed at least one clinic visit during the
intervention period. An additional 27 patients (28%) said
that they would like to return to care and allowed a visit to
be scheduled for them but did not complete a visit before
the end of the intervention. Several others indicated that the
tracer’s call would motivate them to resume treatment at a
new site, but we were not able to conﬁrm that they did so.
Intervention cost and cost per patient returned to care
The main cost of the intervention was the salary of the
tracer, who was employed for 4 months. Costs in 2009
USD are shown in Table 4, using the average exchange rate
over the intervention period (February–May 2009,
R9.36⁄$1.00).
For the 20 patients returned to care by the tracer, the
cost per patient for the intervention was $432⁄patient. This
estimate does not take into account other outcomes of the
intervention, such as the improvement in the accuracy of
the clinic’s records through the ascertainment of the true
status of patients recorded as lost to follow-up; the possible
return to care by some patients as a result of the
intervention after the intervention period ended; and the
possible return to care at other sites of patients for whom
the tracer’s contact provided the necessary motivation. The
average cost per patient attempted to be traced in the
intervention, including those who could not be found
through tracing, was $18.
Because the salary of the patient tracer in this evaluation
was equivalent to that of a professional (senior level)
nurse at the clinic, we also considered the cost of the
intervention had the tracer been a junior enrolled nurse
instead. In this case, assuming the same results of the
intervention, the cost per patient returned to care would
have fallen to $262, and the average cost per patient
attempted to be traced would have been $11. We cannot
know, however, whether a junior nurse, who would likely
have been less experienced than our tracer and lacked
training in social work, would have achieved the same
results.
If patients who had died, transferred to another site, or
been mistakenly reported as lost to follow-up due to
record-keeping errors could have been removed from the
tracer’s original sample prior to starting the intervention,
the number of patients on the tracer’s roster would have
fallen by 39%, and the cost per patient returned to care to
$265 using the tracer’s actual salary or $161 using a junior
nurse’s salary.
Discussion
Over a 4-month period, a dedicated patient tracer working
4 days⁄week was able to track 493 patients and deter-
mine the ﬁnal status of 260 patients previously recorded
as lost to follow-up in clinic records. Just over half (51%)
of these patients were still on treatment, at least by self-
report, at either the same site or at a different site. Another
21% had died. Only 27% of patients admitted to having
stopped treatment entirely, with reasons ranging from
relocation to traditional medicine to fear of disclosure.
Although the intervention cost relatively little to imple-
ment, the modest number of patients known to have been
returned to care by it meant that it was relatively
expensive per patient returned to care. The average cost per
patient returned to care, $432, is equivalent to the cost of
nearly a year of treatment (11.3 months) with ﬁrst-line
therapy at the same site (author’s data). A more junior
tracer would have cost less, but the cost per patient
returned to care ($262) would still have been high. In an
era of tight budgets for HIV⁄AIDS treatment, particularly
in South Africa (Ntutu 2009), spending the equivalent of
even half a year’s worth of treatment to track down an
errant patient may seem unwise, if not unfair to patients on
the waiting list for ART who have not yet had the
opportunity to initiate treatment at all. Improving the
effectiveness of the intervention – increasing the yield of
lost patients who are returned to care – would thus
seem essential for this type of intervention to be advocated
on a larger scale. On the other hand, when the total cost of
the intervention is spread across all the patients in the
Table 4 Intervention costs over 4 months
Item Total cost Cost⁄month
Tracer’s salary and beneﬁts $7306 $1827
Ofﬁce expenses and service $1127 $282
Communications and supplies $176 $44
Patient transport reimbursement $23 $6
Total $8632 $2158
Alternative tracer’s salary and
beneﬁts (junior nurse)
$4224 $1056
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patient fell to $18, and thus represented only a small
increase in the average cost of treatment per patient. If the
intervention were implemented year-round at the same
monthly cost, the average additional cost per patient in
care at the study site would be just $3⁄year, <1% increase
in the average cost of ART at this site (author’s data).
What could be done to improve the intervention? The
most striking aspect of our results is the large proportion of
patients who had either died or reported themselves to
have transferred, and were thus only lost to follow-up from
the perspective of the originating clinic. Greater capacity to
trace patients from one site to another is urgently needed.
The combination of the tremendous mobility of South
African society, in which large numbers of people routinely
relocate between provinces in response to work opportu-
nities; the high cost of seeking treatment in terms of both
transport fares and time; and the pressures of traditional
culture and fear of disclosure make it inevitable that
patients will transfer from one treatment site to another
frequently and often without warning. An information
system that allows the originating site to determine that a
patient has transferred to another clinic would immediately
cut loss to follow-up rates dramatically. Better reporting of
deaths would have a similar effect; in South Africa this can
be achieved by online searching of the national death
registry (Fox et al. 2010). Both changes would allow a
patient tracer to concentrate on patients who are truly lost
to follow-up and can potentially beneﬁt from an interven-
tion, rather than wasting time trying to locate those who
have died or transferred. Excluding from the original
sample the deaths and transfers that were reported to the
tracer would have reduced the cost per patient returned to
care to $265, much less than was actually spent. An
effective system for recording deaths and transfers when
they happen would likely have screened out even more of
the original sample, making the tracer’s efforts that much
more effective and further reducing the cost per patient
returned.
A signiﬁcant minority of patients who discontinued
treatment or transferred to another local clinic indicated
that the main obstacle they faced was conﬂict with
employment. The study site is open only on weekdays and
during working hours. Many patients who use the public
sector have wage jobs that do not allow time off for clinic
visits. Others resist taking time off for fear that it will
reveal their HIV status to their employers. A simple
solution for these patients is to open the clinic in the
evenings and⁄or on Saturdays. While clinic operating costs
may be slightly higher during these times due to overtime
salary requirements, the additional hours may also reduce
waiting times for all patients and extend overall treatment
capacity. Patients requiring weekend visits may also be
willing and able to pay a small fee for this service, an idea
that is under consideration at the study site.
In conclusion, this intervention demonstrated that a
patient tracer can successfully track down and determine
the status of approximately half the patients recorded as
lost to follow-up at a large public sector clinic and can
return a handful of them to care. The cost per patient
returned to care will be high, however, unless better
information systems are implemented to allow patients
who have transferred or died to be excluded from the
intervention. The cost per patient treated by the clinic is
modest, and if most transfers and deaths can be screened
out and the tracer supported over a longer period of time,
this intervention may provide one useful strategy in the
effort to improve long-term patient retention in ART
programs.
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